FIFA monthly Africa national team rankings released Thursday (Africa ranking, world ranking):
Algeria 1 24
Ivory Coast 2 25
Nigeria 3 33
Ghana 4 36
Egypt 5 38
Tunisia 6 42
Sierra Leone 7 50
Cameroon 8 54
Burkina Faso 9 58
Senegal 10 59
Mali 11 60
Libya 12 62
Guinea 13 64
South Africa 14 69
Cape Verde 15 74
Angola 16 75
Benin 17 77
Congo 18 78
Morocco 19 81
Uganda 20 81
Zambia 21 84
Botswana 22 86
Togo 23 87
Zimbabwe 24 90
DR Congo 25 93
Rwanda 26 101
Gabon 27 102
Kenya 28 104
Lesotho 29 105
Malawi 30 106
Mozambique 31 107
Tanzania 32 110
Ethiopia 33 112
Eq. Guinea 34 113
Namibia 35 114
Sudan 36 115
Niger 37 118
Liberia 38 119
C.A.R. 39 120
Guinea-Bissau 40 123
Burundi 41 129
Mauritania 42 133
Chad 43 140
Madagascar 44 143
Gambia 45 148
Swaziland 46 158
Comoros 47 175
Sao Tome 48 177
Seychelles 49 180
S. Sudan 50 185
Mauritius 51 188
Eritrea 52 203
Somalia 53 204
Djibouti 54 205
Next rankings: Sept 18
Vanguard
Related story: FIFA to lift ban on Nigeria participating in international football
Thursday, August 14, 2014
Wednesday, August 13, 2014
Nigeria approves use of experimental Ebola drug
The National Health Research Ethics Committee, Nigeria, has approved the use of an experimental Ebola drug, Zmapp, for treatment of patients infected with the virus.
The committee, which composed research scientists, is a national body under the Federal Ministry of Health.
The endorsement is contained in a statement issued to newsmen by Prof. Clement Adebamowo, Chairman of the committee on Wednesday in Abuja.
The decision by the committee is coming on the heels of Tuesday’s approval by the World Health Organisation (WHO) on the use of Zmapp for treatment of Ebola patients.
“It is ethical to use these treatments in the current situation without first submitting an application to National, State or Institutional Health Research Ethics Committee for prior review and approval.
“In addition, the Committee waives the current requirement that international shipment of any biological samples out of Nigeria should be preceded by the establishment of a Materials Transfer Agreement.
“ This waiver is to promote rapid international response to this global emergency,’’ the statement said.
In the statement, the Nigerian National Code for Health Research Ethics emphasised that all innovative and non-validated treatments should be carefully and adequately documented.
According to the statement, the documentation can form the basis for clinical trials of the efficacy and side effects of the treatment according to established scientific principles.
In the statement, the ethics committee enjoined all agencies, development partners and research scientists to follow the guideline for the rapid resolution of the current emergency.
“The guideline will contribute to preparedness in case of future occurrences and contribution to scientific knowledge.
“It must be noted that all Phase O and Phase I Clinical Trials that may subsequently be designed for treatment of this infection can be approved only by the National Health Research Ethics Committee,’’ it said.
Vanguard
Related stories: Third Ebola death confirmed in Nigeria
Video - Nigeria's challenge to contain ebola
The committee, which composed research scientists, is a national body under the Federal Ministry of Health.
The endorsement is contained in a statement issued to newsmen by Prof. Clement Adebamowo, Chairman of the committee on Wednesday in Abuja.
The decision by the committee is coming on the heels of Tuesday’s approval by the World Health Organisation (WHO) on the use of Zmapp for treatment of Ebola patients.
“It is ethical to use these treatments in the current situation without first submitting an application to National, State or Institutional Health Research Ethics Committee for prior review and approval.
“In addition, the Committee waives the current requirement that international shipment of any biological samples out of Nigeria should be preceded by the establishment of a Materials Transfer Agreement.
“ This waiver is to promote rapid international response to this global emergency,’’ the statement said.
In the statement, the Nigerian National Code for Health Research Ethics emphasised that all innovative and non-validated treatments should be carefully and adequately documented.
According to the statement, the documentation can form the basis for clinical trials of the efficacy and side effects of the treatment according to established scientific principles.
In the statement, the ethics committee enjoined all agencies, development partners and research scientists to follow the guideline for the rapid resolution of the current emergency.
“The guideline will contribute to preparedness in case of future occurrences and contribution to scientific knowledge.
“It must be noted that all Phase O and Phase I Clinical Trials that may subsequently be designed for treatment of this infection can be approved only by the National Health Research Ethics Committee,’’ it said.
Vanguard
Related stories: Third Ebola death confirmed in Nigeria
Video - Nigeria's challenge to contain ebola
Third Ebola death confirmed in Nigeria
A member of the West African regional body Ecowas has become the third person in Nigeria to die of Ebola fever, Ecowas said on Wednesday.
Jatto Asihu Abdulqudir, 36, a protocol assistant, was travelling to an Ecowas function with Liberian Patrick Sawyer, the man who brought Ebola to Nigeria last month. Abdulqudir had been under quarantine. The country has reported eight cases of Ebola since Sawyer arrived on July 20.
"The Commission wishes to reassure staff of all Community institutions all over the entire region that it is taking all necessary steps to guarantee their health and safety," Ecowas said in a statement.
Reuters
Related stories: 2nd ebola case confirmed in Nigeria
Video - Nigeria's challenge to contain ebola
Jatto Asihu Abdulqudir, 36, a protocol assistant, was travelling to an Ecowas function with Liberian Patrick Sawyer, the man who brought Ebola to Nigeria last month. Abdulqudir had been under quarantine. The country has reported eight cases of Ebola since Sawyer arrived on July 20.
"The Commission wishes to reassure staff of all Community institutions all over the entire region that it is taking all necessary steps to guarantee their health and safety," Ecowas said in a statement.
Reuters
Related stories: 2nd ebola case confirmed in Nigeria
Video - Nigeria's challenge to contain ebola
Tuesday, August 12, 2014
Video - Nigeria's challenge to contain ebola
Nigeria may be Africa's biggest economy. But Ebola is certainly proving a challenge to its public health service.
Related stories: Nigeria confirms 10 cases of ebola
Nigerian government declares ebola outbreak a 'national emergency'
Former Newcastle great Shola Ameobi signs one-year deal with 2nd division Turkish club
The Nigeria international, 32, was a free agent following his departure from St James' Park, where, after graduating from the academy, he had been a first-team player for 14 years.
"We want to establish an ambitious team in the league this season, and a strong team continues to strengthen by adding players," said a statement on Gaziantep's official website.
"We have therefore tied Nigerian striker Shola Ameobi - from one of the strongest teams in England, Newcastle United - to us for one year."
Ameobi made 312 appearances for the Magpies, scoring 53 goals, but much of his career on Tyneside was plagued by injury and inconsistent form. He scored Champions League goals against Barcelona in 2002 and against Bayer Leverkusen the following year, while his best return in the Premier League saw him score nine goals in 2005-06.
Ameobi's 11 goals in 21 appearances helped Newcastle win promotion from the Championship in 2010 but he steadily became a fringe player as boss Alan Pardew re-established the club in the top flight.
Gaziantep, who are currently managed by Suat Kaya, finished in 14th place in the TFF First League - the league below the Turkish Super Lig - last season.
Vanguard
Related stories: NFF threaten to petition FIFA for Newcastle and Millwall to release Amoebi and Shittu
Shola Ameobi excited to play for Nigeria
Subscribe to:
Comments (Atom)